The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence
- PMID: 17414961
- DOI: 10.1097/01.bor.0000265447.48722.04
The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence
Abstract
(1) Biologics have had a tremendous impact on the management of rheumatoid arthritis.(2) Three new biologics have been approved or filed for approval for the treatment of rheumatoid arthritis in the last 2 years: abatacept, rituximab, and tocilizumab.(3) The utility of the newer biologics against the background of existing, well established biologics (infliximab, etanercept, adalimumab, and anakinra) has not been evaluated systematically.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
